APA (7th ed.) Citation

Arabloo, J., Azari, S., Gorji, H. A., Rezapour, A., Alipour, V., & Ehsanzadeh, ‬. J. (2023). Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: A systematic review. European Journal of Clinical Pharmacology, 79(11), 1443. https://doi.org/10.1007/s00228-023-03557-6

Chicago Style (17th ed.) Citation

Arabloo, Jalal, Samad Azari, Hasan Abolghasem Gorji, Aziz Rezapour, Vahid Alipour, and ‬Seyed Jafar Ehsanzadeh. "Cost-effectiveness of Brentuximab Vedotin in Hodgkin Lymphoma: A Systematic Review." European Journal of Clinical Pharmacology 79, no. 11 (2023): 1443. https://doi.org/10.1007/s00228-023-03557-6.

MLA (9th ed.) Citation

Arabloo, Jalal, et al. "Cost-effectiveness of Brentuximab Vedotin in Hodgkin Lymphoma: A Systematic Review." European Journal of Clinical Pharmacology, vol. 79, no. 11, 2023, p. 1443, https://doi.org/10.1007/s00228-023-03557-6.